1123 related articles for article (PubMed ID: 26131622)
41. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
42. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
43. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
[TBL] [Abstract][Full Text] [Related]
44. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
45. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
[TBL] [Abstract][Full Text] [Related]
46. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
Kapur S; Zipursky R; Jones C; Remington G; Houle S
Am J Psychiatry; 2000 Apr; 157(4):514-20. PubMed ID: 10739409
[TBL] [Abstract][Full Text] [Related]
47. Plasma levels and estimated dopamine D
Ikai S; Suzuki T; Mimura M; Uchida H
Psychopharmacology (Berl); 2016 Dec; 233(23-24):4003-4010. PubMed ID: 27631410
[TBL] [Abstract][Full Text] [Related]
48. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
49. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
[TBL] [Abstract][Full Text] [Related]
50. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
[TBL] [Abstract][Full Text] [Related]
51. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
52. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
53. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
54. Dopamine D
Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
[TBL] [Abstract][Full Text] [Related]
55. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
56. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
[TBL] [Abstract][Full Text] [Related]
57. Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Yasui-Furukori N; Tsuchimine S; Saito M; Nakagami T; Sugawara N; Fujii A; Kaneko S
J Clin Psychopharmacol; 2011 Oct; 31(5):633-7. PubMed ID: 21869689
[TBL] [Abstract][Full Text] [Related]
58. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat.
Naiker DV; Catts SV; Catts VS; Bedi KS; Bryan-Lluka LJ
Eur J Pharmacol; 2006 Jul; 540(1-3):87-90. PubMed ID: 16730699
[TBL] [Abstract][Full Text] [Related]
59. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
[TBL] [Abstract][Full Text] [Related]
60. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
Mizuno Y; Bies RR; Remington G; Mamo DC; Suzuki T; Pollock BG; Tsuboi T; Watanabe K; Mimura M; Uchida H
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):182-7. PubMed ID: 22230651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
